FDA authorizes antibody treatment for COVID-19

The US Food and Drug Administration (FDA) on Wednesday gave an emergency use authorization to Sotrovimab, the antibody treatment developed by Vir Biotechnology and GlaxoSmithKline for treating mild-to-moderate COVID-19 in people aged 12 years and older, Reuters reports.

Sotrovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy, the FDA clarified.